Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05035745RecruitingPhase 1/Phase 2
Selinexor plus talazoparib for advanced triple-negative breast cancer
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
SingaporeAges 18–99 - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT06771219RecruitingPhase 1
Testing SLV-154 for advanced cancers
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
Newport Beach, CaliforniaAges 12 years+ - NCT06500169Recruiting
Golf exercise study for prostate cancer survivors
This study tests if golf can help men with prostate cancer feel better and stay healthy. It's for men who are on hormone therapy and want to try a gentle, fun exercise.
Los Angeles, CaliforniaAges 55–85 - NCT07094685RecruitingPhase 2
Ivonescimab before surgery for head and neck cancer
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
New Haven, ConnecticutAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT02596490Recruiting
Couple meditation program for metastatic lung cancer and partners
This study tests whether a couple-based meditation program can help people with stage IV non-small cell lung cancer and their romantic partners cope better during treatment. It looks at the experience of both the patient and their partner, not just the patient alone.
Houston, TexasAges 18 years+ - NCT07299409RecruitingPhase 2
Study of sacituzumab govitecan for advanced triple-negative breast cancer
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
Vancouver, British ColumbiaAges 18 years+ - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07339644Recruiting
Lung-Sparing Radiation Guided by Breathing Scans
This study tests a new way to plan radiation for lung tumors. It uses a breathing-guided scan to map healthy and unhealthy parts of the lungs, so radiation can avoid working lung tissue. The goal is to see if this approach spares more healthy lung while still treating the cancer.
ChongqingAges 18–85 - NCT06866782Recruiting
European study on advanced imaging for prostate cancer
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
LeuvenAges 18 years+ - NCT06434350RecruitingPhase 1/Phase 2
Enfortumab vedotin and radiation for advanced bladder cancer
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
Houston, TexasAges 18 years+ - NCT06486883RecruitingPhase 2
T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
GrazAges 18 years+ - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Duarte, CaliforniaAges 15 years+ - NCT06054854Recruiting
Lung Cancer Biomarker Study (BIRD Biobank)
This study collects blood, tissue, and other samples from people with lung nodules, suspected lung cancer, or confirmed lung cancer to find better ways to diagnose and treat the disease. By joining, you help researchers discover new biomarkers that could improve care for future patients.
ToulouseAges 18 years+ - NCT05190094RecruitingPhase 2
Test blood-based laser scan to guide first-line breast cancer treatment
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
BlidaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,511 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.